Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced or Recurrent Breast Cancer
Interventions: DRUG: Entinostat|DRUG: Entinostat(Placebo)|DRUG: Exemestane
Sponsor: Kyowa Kirin Co., Ltd.